Teleflex Incorporated (NYSE:TFX) Receives Consensus Rating of “Moderate Buy” from Analysts

Teleflex Incorporated (NYSE:TFX) has received an average recommendation of “Moderate Buy” from the seven brokerages that are presently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $252.50.

A number of brokerages have commented on TFX. Truist Financial lowered their target price on Teleflex from $227.00 to $200.00 and set a “hold” rating on the stock in a research note on Wednesday, December 18th. Mizuho lowered their price target on Teleflex from $275.00 to $250.00 and set a “neutral” rating for the company in a research note on Friday, November 1st. StockNews.com upgraded Teleflex from a “hold” rating to a “buy” rating in a report on Thursday, November 28th. Needham & Company LLC reissued a “hold” rating on shares of Teleflex in a research report on Monday, December 16th. Finally, Royal Bank of Canada cut their price target on shares of Teleflex from $275.00 to $245.00 and set an “outperform” rating on the stock in a report on Friday, November 1st.

Teleflex Trading Down 0.6 %

NYSE:TFX opened at $177.26 on Wednesday. The stock’s 50-day moving average is $201.26 and its two-hundred day moving average is $219.19. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.42 and a quick ratio of 1.39. The stock has a market cap of $8.23 billion, a PE ratio of 35.24, a price-to-earnings-growth ratio of 1.84 and a beta of 1.16. Teleflex has a fifty-two week low of $171.69 and a fifty-two week high of $256.85.

Teleflex (NYSE:TFX) last released its quarterly earnings data on Thursday, October 31st. The medical technology company reported $3.49 earnings per share for the quarter, beating the consensus estimate of $3.38 by $0.11. The firm had revenue of $764.40 million for the quarter, compared to analyst estimates of $768.68 million. Teleflex had a net margin of 7.85% and a return on equity of 14.19%. The company’s revenue for the quarter was up 2.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.64 EPS. As a group, equities research analysts forecast that Teleflex will post 13.98 earnings per share for the current fiscal year.

Teleflex Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, December 16th. Investors of record on Friday, November 15th were given a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 0.77%. The ex-dividend date of this dividend was Friday, November 15th. Teleflex’s dividend payout ratio (DPR) is currently 27.04%.

Institutional Trading of Teleflex

Hedge funds have recently bought and sold shares of the stock. Oregon Public Employees Retirement Fund grew its holdings in shares of Teleflex by 1.2% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 4,021 shares of the medical technology company’s stock worth $846,000 after purchasing an additional 46 shares in the last quarter. Cromwell Holdings LLC raised its stake in shares of Teleflex by 59.0% in the 3rd quarter. Cromwell Holdings LLC now owns 132 shares of the medical technology company’s stock valued at $33,000 after buying an additional 49 shares in the last quarter. Crossmark Global Holdings Inc. lifted its holdings in shares of Teleflex by 1.9% during the 2nd quarter. Crossmark Global Holdings Inc. now owns 2,779 shares of the medical technology company’s stock worth $584,000 after acquiring an additional 53 shares during the period. Apollon Wealth Management LLC boosted its position in shares of Teleflex by 3.7% during the 3rd quarter. Apollon Wealth Management LLC now owns 1,524 shares of the medical technology company’s stock valued at $377,000 after acquiring an additional 55 shares in the last quarter. Finally, SRS Capital Advisors Inc. raised its position in Teleflex by 0.3% in the third quarter. SRS Capital Advisors Inc. now owns 19,587 shares of the medical technology company’s stock worth $4,844,000 after purchasing an additional 60 shares in the last quarter. 95.62% of the stock is owned by institutional investors.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.